ACAD ACADIA Pharmaceuticals Inc. - Common Stock
$29,78
Cena · Sie 20, 2026
Dane fundamentalne na dzień Sie 5, 2026
Zakres 52 tyg.
$20–$31
90% of range
Ocena Analityków
BUY
27 analysts
Cena Docelowa
$34
+14% upside
P/E (TTM)
12.9
ROE
38.1%
Marża Zysku Netto
36.5%
O ACADIA Pharmaceuticals Inc. - Common Stock Przegląd firmy z Wikipedii
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Czytaj więcej
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Product development
Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.
Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis, major depressive disorder, schizophrenia inadequate response, and schizophrenia negative symptoms.
As of 1997, Acadia was among several companies that licensed compounds from Genzyme's small-molecule compound library.
In 2023, the FDA approved trofinetide (marketed as Daybue) for use in Rett syndrome.
History
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California, as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikring A/S and Dansk Kapitalanlæg Aktieselskab as well as private investor Lars Christiansen. At the time, the company had fifty employees, fourteen of whom were in the Denmark office. The focus of the company in its early years was on genetic screens for receptors, aiming to accelerate early stage drug discovery.
The company planned to conduct an initial public offering (IPO) consisting of 31.6% of the company in 2001, with the intention of raising US$64 million and listing on the NASDAQ exchange under the symbol ACAD. At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. However, the company's IPO, which ultimately took place in May 2004, did not fare as well as expected and netted only US$35 million. At the time, the company had five drugs in development and was running two in human trials. The company had a subsequent round of stock offering in May 2007 which raised US$102 million.
In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics.
Corporate governance
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
== References ==
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
ACAD Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$29.78
Kapitalizacja Rynkowa
$5.07B
P/E (TTM)
12.9
EPS (TTM)
$2.30
Przychody (TTM)
$1.07B
Stopa dywidendy
—
ROE
38.1%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$20 – $31
ACAD Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$1.07B
2016-12-31
→
2025-12-31
EPS
$2.30
2020-12-31
→
2025-12-31
Wolny przepływ pieniężny
$105M
2016-12-31
→
2025-12-31
Marże
36.5%
2016-12-31
→
2023-12-31
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
ACAD
Mediana porównawcza
P/E (TTM)
12.9
13.2
P/S (TTM)
4.7
55.3
P/B
4.1
3.5
Price / FCF (Cena / FCF)
48.2
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
ACAD
Mediana porównawcza
Operating Margin (Marża Operacyjna)
9.8%
—
Net Profit Margin (Marża Zysku Netto)
36.5%
-151.2%
ROA
28.4%
-42.2%
ROE
38.1%
-52.8%
ROIC
24.0%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
ACAD
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
3.8
10.3
Quick Ratio (Wskaźnik Szybkości)
1.1
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
ACAD
Mediana porównawcza
Revenue YoY (Przychody R/R)
11.9%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
27.5%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
19.4%
—
EPS YoY
69.1%
—
Net Income YoY (Zysk Netto R/R)
72.7%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
ACAD
Mediana porównawcza
ACAD Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
27 analityków
- Mocne kupno 7 25,9%
- Kup 14 51,9%
- Trzymaj 5 18,5%
- Sprzedaj 1 3,7%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
20 analityków · 2026-08-18
Mediana
$36.00
Teraz
$29.78
Niski
$17.00
Wysoki
$49.00
Średni cel
$36.00
+20,9%
Średnia cel
$33.85
+13,7%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.30%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $0.18 | $0.06 | 0.12% |
| 31 marca 2026 | $0.02 | $0.06 | -0.04% |
| 31 grudnia 2025 | $1.60 | $0.14 | 1.5% |
| 30 września 2025 | $0.42 | $0.15 | 0.27% |
| 30 czerwca 2025 | $0.16 | $0.14 | 0.02% |
| 31 marca 2025 | $0.11 | $0.11 | -0.00% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | — |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | — |
| ERAS | $1.06B | -8.5 | — | — | -35.7% | — |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | — |
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | — |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | — |
| DYN | $3.23B | -5.6 | — | — | -57.8% | — |
| PBLS | — | — | — | — | — | — |
| CELC | $4.81B | -26.3 | — | — | -244.3% | — |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Cost of Revenue | $89M | $82M | $42M | $10M | $19M | $10M | $11M | $12M | $9M | $3M | · | · | |
| Gross Profit | · | · | $685M | $507M | $473M | $432M | $328M | $211M | $116M | $14M | · | · | |
| R&D Expense | $329M | $303M | $352M | $362M | $239M | $319M | $240M | $187M | $149M | $99M | $74M | $61M | |
| SG&A Expense | $549M | $488M | $407M | $369M | $396M | $389M | $326M | $266M | $255M | $186M | $88M | $33M | |
| Operating Expenses | $967M | $727M | $800M | $741M | $655M | $728M | $586M | $471M | $417M | $290M | $165M | $93M | |
| Operating Income | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M | |
| Other Non-op | $2M | $2M | $5M | $4M | $2M | $-997.0K | $997.0K | $-2M | · | · | · | · | |
| Pretax Income | $139M | $258M | $-51M | $-213M | $-168M | $-281M | $-234M | $-244M | $-288M | $-270M | $-164M | $-92M | |
| Income Tax | $-252M | $32M | $10M | $3M | $351.0K | $611.0K | $876.0K | $1M | $1M | $1M | $330.0K | $0 | |
| Net Income | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| EPS (Diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| Shares (Basic) | 168,356,000 | 165,717,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| Shares (Diluted) | 169,919,000 | 166,362,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| EBITDA | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M |
Bilans 25
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $178M | $320M | $189M | $115M | $147M | $326M | $190M | $135M | $69M | $164M | $102M | $62M | |
| Receivables | $121M | $99M | $98M | $62M | $64M | $48M | $36M | $26M | $17M | $6M | · | · | |
| Inventory | $111M | $92M | $40M | $12M | $14M | $10M | $6M | $4M | $5M | $4M | · | · | |
| Prepaid Expense | $60M | $56M | $39M | $21M | $24M | $26M | $19M | $21M | $8M | $8M | $2M | $1M | |
| Current Assets | $1.06B | $938M | $616M | $508M | $618M | $718M | $760M | $526M | $373M | $548M | $219M | $325M | |
| PP&E (Net) | $8M | $4M | $5M | $6M | $8M | $9M | $3M | $3M | $3M | $3M | $2M | $553.0K | |
| PP&E (Gross) | $17M | $14M | $14M | $14M | $14M | $13M | $9M | $8M | $7M | $6M | $5M | $3M | |
| Accum. Depreciation | $9M | $10M | $10M | $8M | $6M | $4M | $5M | $4M | $4M | $3M | $3M | $2M | |
| Intangibles | $109M | $120M | $65M | $0 | $0 | $1M | $3M | $4M | $6M | $7M | · | · | |
| Other Non-current Assets | $4M | $359.0K | $476.0K | $8M | $4M | $2M | $3M | $2M | $354.0K | $785.0K | $329.0K | $287.0K | |
| Total Assets | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Accounts Payable | $11M | $16M | $18M | $13M | $7M | $8M | $7M | $3M | $9M | $4M | $2M | $2M | |
| Accrued Liabilities | $266M | $379M | $237M | $113M | $89M | $97M | $68M | $56M | $40M | $36M | $20M | $14M | |
| Current Liabilities | $277M | $395M | $254M | $126M | $96M | $106M | $75M | $60M | $49M | $43M | $22M | $16M | |
| Capital Leases | $41M | $42M | $48M | $53M | $56M | $44M | $6M | · | · | · | · | · | |
| Deferred Tax | $11M | $11M | $12M | $13M | $14M | $13M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $19M | $18M | $15M | $9M | $7M | $5M | $3M | $2M | · | · | · | · | |
| Total Liabilities | $337M | $455M | $317M | $187M | $159M | $156M | $84M | $61M | $49M | $43M | $22M | $16M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $15.0K | $14.0K | $12.0K | $12.0K | $10.0K | $10.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | $1.45B | $862M | $808M | |
| Retained Earnings | $-1.81B | $-2.20B | $-2.43B | $-2.37B | $-2.15B | $-1.99B | $-1.70B | $-1.47B | $-1.22B | $-934M | $-663M | $-498M | |
| AOCI | $1M | $292.0K | $24.0K | $-975.0K | $-192.0K | $36.0K | $297.0K | $-372.0K | $-399.0K | $106.0K | $11.0K | $-9.0K | |
| Stockholders' Equity | $1.23B | $733M | $432M | $400M | $541M | $627M | $699M | $479M | $335M | $518M | $200M | $309M | |
| Liabilities + Equity | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Shares Outstanding | 170,309,376 | 166,708,856 | 164,650,219 | 162,064,872 | 161,012,695 | 159,637,771 | 155,275,300 | 143,853,597 | 124,410,552 | 121,367,169 | 101,938,702 | 100,047,331 |
Przepływy pieniężne 13
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $206.0K | |
| Stock-based Comp | $52M | $67M | $66M | $68M | $64M | $84M | $82M | $82M | $76M | $55M | $40M | $16M | |
| Deferred Tax | $-250M | $0 | $0 | $3M | $351.0K | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $11M | $15M | $4M | $0 | $1M | $1M | $1M | $1M | $1M | $985.0K | $0 | $0 | |
| Operating Cash Flow | $110M | $158M | $17M | $-114M | $-126M | $-136M | $-151M | $-167M | $-218M | $-208M | $-122M | $-66M | |
| CapEx | $5M | $523.0K | $50.0K | $0 | $1M | $8M | $1M | $2M | $812.0K | $2M | $2M | $180.0K | |
| Investing Cash Flow | $-303M | $-31M | $32M | $73M | $-71M | $193M | $-166M | $-71M | $92M | $-262M | · | · | |
| Stock Issued | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Net Stock Activity | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Financing Cash Flow | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $534M | · | · | |
| Net Change in Cash | $-143M | $134M | $74M | $-33M | $-179M | $137M | $55M | $68M | $-94M | $63M | $40M | $50M | |
| Taxes Paid | $25M | $20M | $6M | $2M | $1M | $1M | $2M | $1M | $1M | $-365.0K | $415.0K | · | |
| Free Cash Flow | $105M | $157M | $17M | $-114M | $-127M | $-144M | $-152M | $-170M | $-219M | $-212M | $-124M | $-67M |
Rentowność 8
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% | · | · | |
| Operating Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| Net Margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% | -269578.7% | -77062.5% | |
| Pretax Margin | 13.0% | 26.9% | -7.0% | -41.3% | -34.6% | -63.6% | -69.1% | -109.0% | -230.8% | -1558.2% | -269037.7% | · | |
| EBITDA Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| ROA | 28.4% | 23.4% | -9.2% | -33.5% | -22.6% | -36.0% | -35.5% | -53.0% | -61.2% | -69.3% | -60.1% | -35.9% | |
| ROE | 38.1% | 34.6% | -15.4% | -52.3% | -30.3% | -43.9% | -33.9% | -69.8% | -67.8% | -75.6% | -64.6% | -37.6% | |
| ROIC | 24.0% | 27.6% | -20.4% | -56.5% | -31.6% | -45.8% | -35.4% | -51.9% | -87.5% | -52.9% | -82.6% | · |
Płynność i wypłacalność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 | 6.8 | 10.2 | 8.8 | 7.6 | 12.9 | 10.0 | 20.5 | |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 | 3.5 | 3.0 | 2.7 | 1.8 | 4.0 | 4.7 | 3.9 |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 1.0 | 1.1 | 0.8 | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | 0.9 | 1.2 | 1.6 | 0.8 | 0.9 | 1.3 | 2.2 | · | 1.9 | 1.5 | · | · | |
| Receivables Turnover | 9.7 | 9.7 | 9.1 | 8.2 | 8.6 | 10.5 | 11.0 | 10.3 | 10.7 | 5.9 | · | · |
Stopy Wzrostu 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.9% | 31.9% | 40.5% | 6.8% | 9.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.5% | 25.5% | 18.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.4% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 69.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 72.7% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Net Income TTM | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| Market Cap | $4.55B | $3.06B | $5.16B | $2.58B | $3.76B | $8.53B | $6.64B | $2.33B | $3.75B | $3.50B | $3.63B | $3.18B | |
| P/E | 11.6 | 13.5 | -84.6 | -11.9 | -22.2 | -29.9 | · | · | · | · | · | · | |
| P/S | 4.2 | 3.2 | 7.1 | 5.0 | 7.8 | 19.3 | 19.6 | 10.4 | 30.0 | 202.0 | 59575.7 | 26470.9 | |
| P/B | 3.7 | 4.2 | 11.9 | 6.4 | 6.9 | 13.6 | 9.5 | 4.9 | 11.2 | 6.8 | 18.2 | 10.3 | |
| P / Tangible Book | 4.1 | 5.0 | 14.1 | 6.4 | 6.9 | 13.6 | · | · | · | · | · | · | |
| P / Cash Flow | 41.4 | 19.4 | 308.7 | -22.6 | -29.9 | -62.7 | -44.0 | -13.9 | -17.2 | -16.6 | -29.8 | -47.8 | |
| P / FCF | 43.3 | 19.5 | 309.6 | -22.6 | -29.6 | -59.4 | -43.6 | -13.7 | -17.1 | -16.5 | -29.3 | -47.7 | |
| Earnings Yield | 8.6% | 7.4% | -1.2% | -8.4% | -4.5% | -3.4% | · | · | · | · | · | · |
Rachunek zysków i strat 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308M | $268M | $284M | $279M | $265M | $244M | $260M | $250M | $242M | $206M | $231M | $212M | $165M | $118M | $136M | $131M | |
| Cost of Revenue | $28M | $25M | $26M | $22M | $21M | $20M | $22M | $19M | $18M | $23M | $18M | $15M | $7M | $2M | $2M | $2M | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $213M | $197M | $158M | $117M | $134M | $129M | |
| R&D Expense | $82M | $77M | $85M | $88M | $78M | $78M | $101M | $67M | $76M | $60M | $67M | $157M | $59M | $69M | $76M | $81M | |
| SG&A Expense | $160M | $171M | $156M | $133M | $134M | $126M | $130M | $133M | $117M | $108M | $111M | $98M | $96M | $101M | $104M | $78M | |
| Operating Expenses | $270M | $273M | $267M | $243M | $232M | $225M | $106M | $219M | $212M | $191M | $196M | $269M | $162M | $172M | $183M | $162M | |
| Operating Income | $38M | $-5M | $17M | $36M | $32M | $19M | $154M | $32M | $30M | $15M | $35M | $-58M | $3M | $-54M | $-46M | $-31M | |
| Other Non-op | $647.0K | $542.0K | $596.0K | $593.0K | $594.0K | $588.0K | $575.0K | $576.0K | $386.0K | $286.0K | $0 | $2M | $-1M | $5M | $2M | $2M | |
| Pretax Income | $46M | $4M | $26M | $45M | $40M | $28M | $161M | $39M | $37M | $21M | $40M | $-52M | $6M | $-45M | $-41M | $-26M | |
| Income Tax | $15M | $344.0K | $-247M | $-27M | $14M | $9M | $17M | $6M | $4M | $4M | $-6M | $13M | $5M | $-2M | $835.0K | $768.0K | |
| Net Income | $32M | $4M | $274M | $72M | $27M | $19M | $144M | $33M | $33M | $17M | $46M | $-65M | $1M | $-43M | $-42M | $-27M | |
| EPS (Basic) | $0.18 | $0.02 | $1.62 | $0.43 | $0.16 | $0.11 | $0.87 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| EPS (Diluted) | $0.18 | $0.02 | $1.61 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| Shares (Basic) | 171,603,000 | 170,517,000 | -335,115,000 | 168,836,000 | 167,827,000 | 166,808,000 | -330,606,000 | 165,974,000 | 165,551,000 | 164,798,000 | -326,136,000 | 164,234,000 | 163,458,000 | 162,263,000 | 128,494 | 161,852 | |
| Shares (Diluted) | 172,851,000 | 172,706,000 | -337,080,000 | 170,650,000 | 168,681,000 | 167,668,000 | -332,613,000 | 166,178,000 | 166,174,000 | 166,623,000 | -327,724,000 | 164,234,000 | 165,046,000 | 162,263,000 | 128,494 | 161,852 | |
| EBITDA | $38M | $-5M | · | $36M | $32M | $19M | · | $32M | $30M | $15M | · | $-58M | $3M | $-54M | · | $-31M |
Bilans 24
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $385M | $282M | $178M | $258M | $254M | $218M | $320M | $155M | $177M | $205M | $189M | $98M | $108M | $291M | $115M | $155M | |
| Receivables | $151M | $135M | $121M | $116M | $108M | $106M | $99M | $98M | $104M | $95M | · | $93M | $82M | $66M | · | $56M | |
| Inventory | $109M | $112M | $111M | $106M | $111M | $103M | $92M | $87M | $86M | $67M | · | $25M | $14M | $11M | · | $12M | |
| Prepaid Expense | $69M | $65M | $60M | $61M | $53M | $53M | $56M | $52M | $46M | $43M | · | $38M | $24M | $24M | · | $23M | |
| Current Assets | $1.22B | $1.10B | $1.06B | $1.08B | $961M | $871M | $938M | $788M | $729M | $675M | · | $499M | $493M | $503M | · | $522M | |
| PP&E (Net) | $17M | $15M | $8M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $17M | · | · | · | $14M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $10M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $103M | $106M | $109M | $112M | $114M | $117M | $120M | $106M | $108M | $110M | · | $67M | $68M | $70M | · | · | |
| Other Non-current Assets | $4M | $4M | $4M | $3M | $2M | $1M | $359.0K | $359.0K | $476.0K | $476.0K | · | $475.0K | $11M | $12M | · | $6M | |
| Total Assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Accounts Payable | $45M | $12M | $11M | $22M | $20M | $18M | $16M | $19M | $20M | $19M | · | $12M | $19M | $17M | · | $10M | |
| Accrued Liabilities | $317M | $293M | $266M | $335M | $310M | $284M | $379M | $325M | $318M | $311M | · | $197M | $169M | $207M | · | $107M | |
| Current Liabilities | $361M | $306M | $277M | $357M | $330M | $303M | $395M | $344M | $338M | $331M | · | $210M | $188M | $224M | · | $117M | |
| Capital Leases | $60M | $39M | $41M | $43M | $45M | $45M | $42M | $40M | $47M | $49M | · | $48M | $50M | $51M | · | $54M | |
| Deferred Tax | · | · | $11M | · | · | · | $11M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $15M | $13M | $19M | $14M | $29M | $20M | $18M | $15M | $12M | $11M | · | $13M | $9M | $5M | · | $6M | |
| Total Liabilities | $436M | $357M | $337M | $413M | $403M | $367M | $455M | $400M | $397M | $391M | · | $270M | $247M | $281M | · | $177M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | · | $16.0K | $16.0K | $16.0K | · | $16.0K | |
| Retained Earnings | $-1.78B | $-1.81B | $-1.81B | $-2.09B | $-2.16B | $-2.19B | $-2.20B | $-2.35B | $-2.38B | $-2.41B | · | $-2.48B | $-2.41B | $-2.41B | · | $-2.33B | |
| AOCI | $-958.0K | $-563.0K | $1M | $989.0K | $406.0K | $437.0K | $292.0K | $858.0K | $-339.0K | $-229.0K | · | $-319.0K | $-535.0K | $-220.0K | · | $-1M | |
| Stockholders' Equity | $1.31B | $1.25B | $1.23B | $917M | $822M | $765M | $733M | $577M | $517M | $464M | $432M | $362M | $396M | $374M | $400M | $426M | |
| Liabilities + Equity | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Shares Outstanding | 172,132,442 | 171,086,205 | 170,309,376 | 169,146,043 | 168,607,881 | 167,116,045 | 166,708,856 | 166,351,715 | 165,853,301 | 164,959,736 | · | 163,968,949 | 163,355,787 | 162,384,178 | · | 161,871,806 |
Przepływy pieniężne 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $17M | $15M | $13M | $13M | $14M | $11M | $10M | $26M | $16M | $15M | $18M | $19M | $15M | $15M | $14M | $18M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $2M | $2M | $5M | $1M | $1M | $1M | $0 | $0 | $0 | |
| Operating Cash Flow | $101M | $34M | $-49M | $74M | $64M | $20M | $40M | $63M | $25M | $29M | $85M | $-59M | $8M | $-18M | $-24M | $-727.0K | |
| CapEx | $5M | $5M | $4M | $388.0K | $297.0K | $0 | $453.0K | $70.0K | · | · | $0 | · | · | · | $0 | $0 | |
| Investing Cash Flow | $-9M | $66M | $-56M | $-79M | $-43M | $-124M | $122M | $-82M | $-56M | $-14M | $-347.0K | $34M | $-194M | $193M | $-18M | $15M | |
| Stock Issued | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Stock Activity | · | $4M | · | · | · | $2M | · | · | · | $1M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Change in Cash | $103M | $105M | $-82M | $4M | $37M | $-102M | $164M | $-19M | $-28M | $16M | $90M | $-12M | $-181M | $176M | $-40M | $15M | |
| Free Cash Flow | · | $29M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| Net Margin | 10.2% | 1.4% | · | 25.8% | 10.1% | 7.8% | · | 13.1% | 13.8% | 8.0% | · | -30.8% | 0.67% | -36.3% | · | -20.8% | |
| Pretax Margin | 15.1% | 1.5% | · | 16.0% | 15.2% | 11.4% | · | 15.5% | 15.4% | 10.2% | · | -24.6% | 3.8% | -37.9% | · | -20.2% | |
| EBITDA Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| ROA | 2.1% | 0.27% | · | 6.2% | 2.5% | 1.9% | · | 4.1% | 4.3% | 2.2% | · | -10.5% | 0.18% | -6.7% | · | -4.1% | |
| ROE | 3.0% | 0.36% | · | 9.6% | 4.0% | 3.1% | · | 7.0% | 7.3% | 4.0% | · | -16.6% | 0.27% | -10.5% | · | -5.5% | |
| ROIC | 2.0% | -0.34% | · | 6.3% | 2.6% | 1.7% | · | 4.6% | 5.3% | 2.6% | · | -19.9% | 0.13% | -13.7% | · | -7.5% |
Płynność i wypłacalność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.6 | · | 3.0 | 2.9 | 2.9 | · | 2.3 | 2.2 | 2.0 | · | 2.4 | 2.6 | 2.2 | · | 4.5 | |
| Quick Ratio | 1.5 | 1.4 | · | 1.0 | 1.1 | 1.1 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | 1.0 | 1.6 | · | 1.8 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.6 | · | 0.8 | 0.6 | 0.1 | · | 0.2 | |
| Receivables Turnover | 2.4 | 2.2 | · | 2.6 | 2.5 | 2.4 | · | 2.6 | 2.6 | 2.6 | · | 2.9 | 2.2 | 1.8 | · | 2.2 |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.12B | $1.06B | · | $1.04B | $1.00B | $943M | · | $929M | $891M | $814M | · | $632M | $551M | $520M | · | $512M | |
| Net Income TTM | $134M | $121M | · | $150M | $112M | $102M | · | $129M | $31M | $-2M | · | $-149M | $-111M | $-146M | · | $-217M | |
| Market Cap | $4.35B | $3.81B | · | $3.61B | $3.64B | $2.78B | · | $2.56B | $2.70B | $3.05B | · | $3.42B | $3.91B | $3.06B | · | $2.65B | |
| P/E | 32.4 | 31.4 | · | 24.0 | 32.2 | 27.2 | · | 19.7 | 90.3 | -1849.0 | · | -22.7 | -34.7 | -20.7 | · | -12.1 | |
| P/S | 3.9 | 3.6 | · | 3.5 | 3.6 | 2.9 | · | 2.8 | 3.0 | 3.7 | · | 5.4 | 7.1 | 5.9 | · | 5.2 | |
| P/B | 3.3 | 3.1 | · | 3.9 | 4.4 | 3.6 | · | 4.4 | 5.2 | 6.6 | · | 9.4 | 9.9 | 8.2 | · | 6.2 | |
| P / Tangible Book | 3.6 | 3.3 | · | 4.5 | 5.1 | 4.3 | · | 5.4 | 6.6 | 8.6 | · | 11.6 | 11.9 | 10.0 | · | 6.2 | |
| P / Cash Flow | · | 112.1 | · | · | · | 136.6 | · | · | · | 104.9 | · | · | · | -170.4 | · | · | |
| P / FCF | · | 132.4 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 3.1% | 3.2% | · | 4.2% | 3.1% | 3.7% | · | 5.1% | 1.1% | -0.05% | · | -4.4% | -2.9% | -4.8% | · | -8.2% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $1.07B | $958M | $726M | $517M | $484M |
| Marża Brutto % | — | — | 94.3% | 98.0% | 97.8% |
| Marża Operacyjna % | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| Zysk netto | $391M | $226M | $-61M | $-216M | $-168M |
| Rozwodniony EPS | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 |
| Wskaźnik Szybkości | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $105M | $157M | $17M | $-114M | $-127M |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Sygnały transakcyjne Ostatnie sygnały kupna/sprzedaży z ceną wejścia i wskaźnikiem ryzyka/zysku
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 388 emitentów · $3.3B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 56 (+4 vs poprzedni kw.) | 36 (+8 vs poprzedni kw.) | 136 (+11 vs poprzedni kw.) | 101 (-12 vs poprzedni kw.) | +4.8M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $1 085 696 471 | 42 912 904 | 32,71% | Akcje |
| STATE STREET CORP | $229 628 164 | 9 076 212 | 6,92% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $223 612 785 | 8 838 450 | 6,74% | Akcje |
| RTW INVESTMENTS, LP | $180 756 457 | 7 144 524 | 5,45% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $145 822 875 | 5 763 750 | 4,39% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $88 971 384 | 3 516 656 | 2,68% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $73 088 127 | 2 888 204 | 2,20% | Akcje |
| Palo Alto Investors LP | $72 461 629 | 2 864 096 | 2,18% | Akcje |
| Qube Research & Technologies Ltd | $61 899 233 | 2 446 610 | 1,86% | Akcje |
| Point72 Asset Management, L.P. | $61 559 150 | 2 433 168 | 1,85% | Akcje |
| CITADEL ADVISORS LLC | $53 414 195 | 2 111 233 | 1,61% | Akcje |
| Pictet Asset Management Holding SA | $50 146 450 | 1 983 198 | 1,51% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $49 826 959 | 1 969 445 | 1,50% | Akcje |
| MARSHALL WACE, LLP | $44 649 289 | 1 764 794 | 1,35% | Akcje |
| BRAIDWELL LP | $41 653 895 | 1 646 399 | 1,25% | Akcje |
| NORGES BANK | $41 069 692 | 1 623 308 | 1,24% | Akcje |
| Frazier Life Sciences Management, L.P. | $36 386 409 | 1 438 198 | 1,10% | Akcje |
| Artisan Partners Limited Partnership | $33 525 890 | 1 325 134 | 1,01% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $32 449 679 | 1 282 596 | 0,98% | Akcje |
| GOLDMAN SACHS GROUP INC | $32 070 584 | 1 267 612 | 0,97% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $30 520 301 | 1 206 336 | 0,92% | Akcje |
| D. E. Shaw & Co., Inc. | $28 330 257 | 1 119 773 | 0,85% | Akcje |
| Allspring Global Investments Holdings, LLC | $26 143 513 | 1 037 441 | 0,79% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $23 452 898 | 926 992 | 0,71% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $23 082 961 | 912 370 | 0,70% | Akcje |
| BANK OF AMERICA CORP /DE/ | $21 702 062 | 857 789 | 0,65% | Akcje |
| PANAGORA ASSET MANAGEMENT INC | $17 985 922 | 710 906 | 0,54% | Akcje |
| Fisher Asset Management, LLC | $17 690 535 | 699 230 | 0,53% | Akcje |
| Allianz Asset Management GmbH | $15 730 341 | 706 664 | 0,47% | Akcje |
| RICE HALL JAMES & ASSOCIATES, LLC | $15 657 841 | 618 887 | 0,47% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $14 925 077 | 589 924 | 0,45% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $14 771 456 | 583 852 | 0,45% | Akcje |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $12 903 000 | 510 000 | 0,39% | Akcje |
| Hudson Bay Capital Management LP | $11 764 500 | 465 000 | 0,35% | Akcje |
| GLENMEDE TRUST CO NA | $11 656 544 | 460 733 | 0,35% | Akcje |
| JUPITER ASSET MANAGEMENT LTD | $11 599 190 | 458 466 | 0,35% | Akcje |
| Public Sector Pension Investment Board | $11 014 988 | 435 375 | 0,33% | Akcje |
| MACKENZIE FINANCIAL CORP | $10 646 872 | 420 825 | 0,32% | Akcje |
| Ishara Investments LP | $10 373 000 | 410 000 | 0,31% | Akcje |
| TWO SIGMA ADVISERS, LP | $9 888 042 | 370 200 | 0,30% | Akcje |
| Balyasny Asset Management L.P. | $9 817 007 | 388 024 | 0,30% | Akcje |
| BlackRock, Inc. | $9 281 482 | 366 857 | 0,28% | Akcje |
| SPHERA FUNDS MANAGEMENT LTD. | $9 020 310 | 356 534 | 0,27% | Akcje |
| AMERIPRISE FINANCIAL INC | $8 039 177 | 317 754 | 0,24% | Akcje |
| PRUDENTIAL FINANCIAL INC | $7 985 313 | 315 625 | 0,24% | Akcje |
| Alyeska Investment Group, L.P. | $7 850 261 | 310 287 | 0,24% | Akcje |
| RHUMBLINE ADVISERS | $7 663 389 | 302 902 | 0,23% | Akcje |
| Schonfeld Strategic Advisors LLC | $7 189 171 | 284 157 | 0,22% | Akcje |
| Edgestream Partners, L.P. | $7 167 515 | 283 301 | 0,22% | Akcje |
| Logos Global Management LP | $6 325 000 | 250 000 | 0,19% | Akcje |
| LAZARD ASSET MANAGEMENT LLC | $6 263 496 | 247 569 | 0,19% | Akcje |
| FMR LLC | $6 052 317 | 239 222 | 0,18% | Akcje |
| Swiss National Bank | $5 841 871 | 230 904 | 0,18% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $5 432 213 | 214 712 | 0,16% | Akcje |
| ALPS ADVISORS INC | $4 985 340 | 197 049 | 0,15% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $4 926 239 | 194 713 | 0,15% | Akcje |
| Legal & General Group Plc | $4 918 245 | 194 397 | 0,15% | Akcje |
| FIRST TRUST ADVISORS LP | $4 664 965 | 184 386 | 0,14% | Akcje |
| NEW YORK STATE COMMON RETIREMENT FUND | $4 364 807 | 172 522 | 0,13% | Akcje |
| Birchview Capital, LP | $4 326 300 | 171 000 | 0,13% | Akcje |
| MARTINGALE ASSET MANAGEMENT L P | $4 247 693 | 167 893 | 0,13% | Akcje |
| Tetragon Partners GP Ltd | $4 247 238 | 167 875 | 0,13% | Akcje |
| GREAT LAKES ADVISORS, LLC | $3 822 526 | 151 088 | 0,12% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $3 635 306 | 143 688 | 0,11% | Akcje |
| STEMPOINT CAPITAL LP | $3 622 125 | 143 167 | 0,11% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $3 585 329 | 161 066 | 0,11% | Akcje |
| Squarepoint Ops LLC | $3 542 329 | 140 013 | 0,11% | Akcje |
| ORBIMED ADVISORS LLC | $3 466 100 | 137 000 | 0,10% | Akcje |
| Erste Asset Management GmbH | $3 369 240 | 133 700 | 0,10% | Akcje |
| Emerald Investment Advisers, LLC | $3 333 326 | 131 752 | 0,10% | Akcje |
| Caption Management, LLC | $3 289 000 | 130 000 | 0,10% | Opcja sprzedaży |
| VANGUARD ASSET MANAGEMENT, Ltd | $3 130 217 | 123 724 | 0,09% | Akcje |
| WELLS FARGO & COMPANY/MN | $3 084 475 | 121 916 | 0,09% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3 077 311 | 138 244 | 0,09% | Akcje |
| Longaeva Partners L.P. | $2 968 145 | 117 318 | 0,09% | Akcje |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $2 948 791 | 116 553 | 0,09% | Akcje |
| Trexquant Investment LP | $2 935 357 | 116 022 | 0,09% | Akcje |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $2 909 778 | 115 011 | 0,09% | Akcje |
| JONES FINANCIAL COMPANIES LLLP | $2 868 477 | 113 289 | 0,09% | Akcje |
| Rafferty Asset Management, LLC | $2 789 426 | 110 254 | 0,08% | Akcje |
| Nan Fung Group Holdings Ltd | $2 605 495 | 102 984 | 0,08% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $2 406 232 | 95 108 | 0,07% | Akcje |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $2 344 000 | 92 648 | 0,07% | Akcje |
| ROYCE & ASSOCIATES LP | $2 324 691 | 91 885 | 0,07% | Akcje |
| HOHIMER WEALTH MANAGEMENT, LLC | $2 322 540 | 91 800 | 0,07% | Akcje |
| Point72 Europe (London) LLP | $2 305 047 | 108 015 | 0,07% | Akcje |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $2 134 076 | 79 898 | 0,06% | Akcje |
| Campbell & CO Investment Adviser LLC | $2 108 527 | 83 341 | 0,06% | Akcje |
| Verdad Advisers, LP | $2 090 514 | 82 629 | 0,06% | Akcje |
| VOYA INVESTMENT MANAGEMENT LLC | $2 072 576 | 81 920 | 0,06% | Akcje |
| CITADEL ADVISORS LLC | $2 049 300 | 81 000 | 0,06% | Opcja kupna |
| GUGGENHEIM CAPITAL LLC | $1 979 776 | 78 252 | 0,06% | Akcje |
| WESBANCO BANK INC | $1 978 460 | 78 200 | 0,06% | Akcje |
| Phocas Financial Corp. | $1 954 299 | 77 245 | 0,06% | Akcje |
| MetLife Investment Management, LLC | $1 899 043 | 75 061 | 0,06% | Akcje |
| STATE OF WISCONSIN INVESTMENT BOARD | $1 850 493 | 73 142 | 0,06% | Akcje |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1 788 331 | 70 685 | 0,05% | Akcje |
| Freestone Grove Partners LP | $1 755 643 | 69 393 | 0,05% | Akcje |
| CenterBook Partners LP | $1 743 878 | 68 928 | 0,05% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $1 722 930 | 68 100 | 0,05% | Akcje |
Insiderzy spółki 39 insiderów · 20 dyrektorzy generalni · 20 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Stephen Davis | CEO | 6 stycznia 2024 M | 96 521 | 0 | 0 | $0 |
| Uli Hacksell | CEO | 17 lutego 2015 M | 115 549 | 0 | 0 | $0 |
| Elena Ridloff | EVP and CFO | 29 kwietnia 2021 M | 10 553 | 0 | 0 | $0 |
| Todd S. Young | EVP AND CFO | 15 października 2018 A | — | 0 | 0 | $0 |
| Thomas H Aasen | EXEC VP, CFO AND CBO | 4 kwietnia 2014 M | 0 | 0 | 0 | $0 |
| Srdjan R. Stankovic | President | 21 listopada 2022 M | 61 234 | 0 | 0 | $0 |
| Mark R Brann | President & CSO | 16 czerwca 2006 S | 317 756 | 0 | 0 | $0 |
| Brendan Teehan | EVP, COO, Head of Commercial | 6 stycznia 2024 M | 30 949 | 0 | 0 | $0 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 29 lipca 2026 M | 18 994 | 0 | 2 | $-432 662 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 26 czerwca 2026 S | 13 088 | 0 | 2 | $-412 253 |
| Austin D. Kim | EVP,General Counsel, Secretary | 6 stycznia 2024 M | 46 901 | 0 | 0 | $0 |
| Douglas J Williamson | Executive VP, Research & Dev | 10 lutego 2023 A | — | 0 | 0 | $0 |
| Michael J. Yang | EVP and CCO | 6 stycznia 2021 M | 8 059 | 0 | 0 | $0 |
| Eric Alejandro Miller | Controller & PAO | 15 października 2019 M | 270 | 0 | 0 | $0 |
| Glenn Baity | EVP AND GC | 18 kwietnia 2018 A | 83 734 | 0 | 0 | $0 |
| Terrence O Moore | EVP, CHIEF COMMERCIAL OFFICER | 8 marca 2017 A | 1 671 | 0 | 0 | $0 |
| Roger Mills | EVP, DEVELOPMENT AND CMO | 20 marca 2015 A | 18 550 | 0 | 0 | $0 |
| Bo-Ragnar Tolf | VP/Mg. Dir. ACADIA Pharma AB | 8 lipca 2009 M | 20 000 | 0 | 0 | $0 |
| Brian Lundstrom | Sr. VP, Bus. Development | 7 marca 2008 A | 0 | 0 | 0 | $0 |
| Robert E Davis | Exec. VP, Drug Discovery | 11 marca 2005 A | — | 0 | 0 | $0 |
| Adora Ndu | Dyrektor | 29 maja 2026 A | 32 908 | 0 | 0 | $0 |
| Elizabeth A. Garofalo | Dyrektor | 29 maja 2026 A | 33 489 | 0 | 0 | $0 |
| Jonathan Poole | Dyrektor | 29 maja 2026 A | 2 010 | 0 | 0 | $0 |
| James M Daly | Dyrektor | 29 maja 2026 A | 12 148 | 0 | 0 | $0 |
| Laura Brege | Dyrektor | 29 maja 2026 A | 23 202 | 0 | 0 | $0 |
| Edmund Harrigan | Dyrektor | 29 maja 2026 A | 43 148 | 0 | 0 | $0 |
| Daniel B Soland | Dyrektor | 1 czerwca 2023 A | 28 002 | 0 | 0 | $0 |
| Mary Ann Gray | Dyrektor | 7 czerwca 2016 M | 149 476 | 0 | 0 | $0 |
| Leslie L Iversen | Dyrektor | 18 kwietnia 2016 M | 36 127 | 0 | 0 | $0 |
| Lester J Ph D Kaplan | Dyrektor | 11 sierpnia 2015 M | 17 000 | 0 | 0 | $0 |
| William Mcdowall Wells | Dyrektor | 15 czerwca 2015 A | 0 | 0 | 0 | $0 |
| Torsten Rasmussen | Dyrektor | 15 czerwca 2015 A | 8 500 | 0 | 0 | $0 |
| Michael T Borer | Dyrektor | 15 czerwca 2015 A | 0 | 0 | 0 | $0 |
| Gordon M Binder | Dyrektor | 12 czerwca 2009 A | 14 364 | 0 | 0 | $0 |
| Alan G Walton | Dyrektor | 12 czerwca 2009 A | 25 979 | 0 | 0 | $0 |
| Martien Van Osch | Dyrektor | 10 czerwca 2005 A | 1 168 892 | 0 | 0 | $0 |
| GORDON CARL L | Dyrektor | 20 kwietnia 2005 A | 774 006 | 0 | 0 | $0 |
| Mark C. Schneyer | — | 6 sierpnia 2026 M | 67 828 | 0 | 3 | $-587 248 |
| John Joseph Kaiser | — | 20 października 2008 A | — | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 6 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB3 LLC ×14 zgłoszenia | 26 lutego 2026 | 25,40% | Aneks | — | SEC |
| Baker Bros. Advisors, LLC, Felix J. Baker, Julian C. Baker ×4 zgłoszenia | 6 czerwca 2013 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca | 2 maja 2005 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca | 2 maja 2005 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca | 2 maja 2005 | — | Pierwotne zgłoszenie | — | SEC |
| Oxford Bioscience Partners IV L.P., mRNA Fund II L.P., OBP Management IV L.P., Jeffrey T. Barnes, Mark P. Carthy, Jonathan J. Fleming, Michael E. Lytton, Alan G. Walton | 29 kwietnia 2005 | — | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 78 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2,35% | 175 740 NS | 31 maja 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,32% | 34 855 NS | 30 kwietnia 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,85% | 195 542 NS | 30 kwietnia 2026 | N-PORT |
| ROSC · Lattice Strategies Trust | 0,56% | 13 607 NS | 30 kwietnia 2026 | N-PORT |
| OASC · Unified Series Trust | 0,39% | 15 269 NS | 31 maja 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,27% | 61 606 NS | 30 kwietnia 2026 | N-PORT |
| BFOR · ALPS ETF Trust | 0,24% | 24 003 NS | 31 maja 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,20% | 89 945 NS | 31 maja 2026 | N-PORT |
| BIB · ProShares Trust | 0,19% | 6 303 NS | 31 maja 2026 | N-PORT |
| PSC · Principal Exchange-Traded Funds | 0,18% | 167 685 NS | 30 czerwca 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,17% | 6 035 NS | 30 kwietnia 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 47 683 NS | 30 kwietnia 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,14% | 81 552 NS | 30 kwietnia 2026 | N-PORT |
| SAA · ProShares Trust | 0,12% | 1 498 NS | 31 maja 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,09% | 115 210 NS | 31 maja 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,08% | 526 641 NS | 30 kwietnia 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 16 957 NS | 30 kwietnia 2026 | N-PORT |
| ITWO · ProShares Trust | 0,07% | 5 921 NS | 31 maja 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,06% | 599 784 NS | 31 maja 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,04% | 54 956 NS | 30 kwietnia 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,04% | 2 306 NS | 30 kwietnia 2026 | N-PORT |
| UWM · ProShares Trust | 0,04% | 4 631 NS | 31 maja 2026 | N-PORT |
| AFSM · First Trust Exchange-Traded Fund VI… | 0,03% | 1 517 NS | 31 maja 2026 | N-PORT |
| URTY · ProShares Trust | 0,03% | 4 683 NS | 31 maja 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,03% | 136 NS | 31 maja 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,03% | 4 944 NS | 30 kwietnia 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 348 165 NS | 30 kwietnia 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,02% | 112 668 NS | 30 kwietnia 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 4 762 NS | 31 maja 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 118 NS | 31 maja 2026 | N-PORT |
| EBI · RBB Fund Trust | 0,01% | 3 525 NS | 31 maja 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 15 114 NS | 30 kwietnia 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 44 472 NS | 31 maja 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,01% | 33 470 NS | 30 kwietnia 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 3 816 NS | 30 kwietnia 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 35 634 NS | 30 kwietnia 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 77 742 NS | 31 maja 2026 | N-PORT |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,00% | 321 NS | 31 maja 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,00% | 6 176 NS | 30 kwietnia 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VB · VANGUARD INDEX FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VBK · VANGUARD INDEX FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | — | — | 15 lipca 2026 | Dziennie |
| VIOO · VANGUARD ADMIRAL FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VIOG · VANGUARD ADMIRAL FUNDS | — | — | 30 lipca 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 lipca 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 lipca 2026 | Dziennie |
| IJR · iShares Trust | — | — | 13 sierpnia 2026 | Dziennie |